Lawmakers Demand IRS Tax Clarity as Cannabis Rescheduling Advances

Congressional representatives are pressuring the Internal Revenue Service to deliver immediate tax guidance for cannabis businesses as the Drug Enforcement Administration's rescheduling process nears completion. The push comes as operators across the industry prepare for the transition from Schedule I to Schedule III classification, which would fundamentally alter the tax landscape for publicly traded cannabis companies and private operators alike.

The rescheduling timeline creates urgency around Section 280E relief, the federal tax provision that currently prohibits cannabis businesses from deducting standard business expenses. This tax burden has compressed margins across the sector, with major operators like Curaleaf Holdings (CURLF) and Green Thumb Industries (GTBIF) reporting effective tax rates exceeding 70% in recent quarters. The elimination of 280E restrictions could deliver immediate margin expansion worth hundreds of millions in aggregate savings industry-wide.

Tax policy uncertainty poses operational challenges for cannabis companies already navigating complex state-by-state regulatory frameworks. Multi-state operators have structured their businesses around current tax limitations, with many maintaining separate subsidiaries to optimize their 280E exposure. Schedule III reclassification would require rapid restructuring of these arrangements, making clear IRS guidance essential for compliance and strategic planning.

The congressional intervention reflects broader momentum around federal cannabis reform, with rescheduling representing the most significant federal policy shift since prohibition began. However, Schedule III classification maintains federal oversight through the Food and Drug Administration, creating new regulatory pathways that could reshape how cannabis products reach consumers. This hybrid approach preserves state-level programs while opening doors for interstate commerce and banking normalization.

Industry analysts view prompt IRS guidance as critical for maintaining market stability during the transition period. Without clear direction on tax treatment, cannabis operators face potential compliance risks that could trigger enforcement actions or financial penalties. The lawmakers' intervention signals recognition that regulatory clarity drives capital formation and operational efficiency in emerging markets, particularly for an industry that has operated under federal prohibition for decades.